Introduction
The pursuit of genetic predictors of treatment response or adverse events has been, in recent years, the focus of many investigators around the world. These pharmacogenetic studies were aimed not only at the discovery of clinically useful predictors but also at untangling pathophysiology and shedding light on mechanisms of drug action. So far, few studies have succeeded in identifying genetic markers of sufficient clinical utility that they can be used in pretreatment pharmacogenetic tests. Perhaps the best-known example is warfarin therapy, where three polymorphisms predictive of optimal dose have been identified (Wadelius et al., 2005) . The U.S. Food & Drug Administration now reminds prescribers that patients who carry certain alleles may require dose adjustment, although the costeffectiveness of genetic testing for these alleles is not clear (Patrick et al., 2009) .
Major depressive disorder (MDD), an important public health priority that is predicted to be the second leading cause of death and disability in the coming decade (Murray and Lopez, 1996) , has been the focus of multiple genetic and pharmacogenetic studies. So far, candidate gene studies have yielded results that lack sufficient predictive power to be useful in a clinical setting. The candidates for these studies were derived from an understanding of depression and the mechanism of action of antidepressant drugs, both of which are quite limited. Variation in genes involved in the synthesis, transport and metabolism of amines, as well as, pharmacokinetic and pharmacodynamic targets of antidepressants have been at the forefront of these investigations (reviewed in (Drago et al., 2009) ). With the development of genome-wide platforms, the implementation of a "hypothesis-free" approach that would interrogate, at least in part, all known genes became the favored strategy to uncover novel and more clinically representative candidates. This review aims at discussing the results and limitations of genome-wide association studies of antidepressant treatment in major depressive disorder and potential future directions in this field. 
